MedTrace Logo

Carbohydrate Antigen 19-9 in Colorectal Cancer

NCT04999072 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4972

Last updated 2021-08-10

No results posted yet for this study

Summary

4,972 patients who underwent surgery for primary CRC between January 2004 and December 2015 at Seoul National University Hospital were retrospectively reviewed.

CA19-9 is a valuable prognostic and diagnostic marker for CRC when used adjunctively with CEA and can be a supplementary marker with CEA to improve sensitivity, especially with elevated preoperative CA19-9.

Conditions

Interventions

PROCEDURE

Colectomy for colon cancer

Segmental or total colectomy was performed for colorectal cancer.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Min Jung Kim, M.D. · Seoul National University Hospital, Republic of Korea

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-19
Primary Completion
2021-09-01
Completion
2021-12-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999072 on ClinicalTrials.gov